956 related articles for article (PubMed ID: 21115425)
1. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
2. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
Mohd Sharial MSN; Crown J; Hennessy BT
Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
4. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer.
Mayer I
Clin Adv Hematol Oncol; 2013 Apr; 11(4):217-24. PubMed ID: 23604238
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
[TBL] [Abstract][Full Text] [Related]
6. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Gajria D; Chandarlapaty S
Expert Rev Anticancer Ther; 2011 Feb; 11(2):263-75. PubMed ID: 21342044
[TBL] [Abstract][Full Text] [Related]
7. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Brufsky AM
Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
Morrow PK; Zambrana F; Esteva FJ
Breast Cancer Res; 2009; 11(4):207. PubMed ID: 19664181
[TBL] [Abstract][Full Text] [Related]
9. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
[TBL] [Abstract][Full Text] [Related]
10. FOXO1A is a target for HER2-overexpressing breast tumors.
Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
[TBL] [Abstract][Full Text] [Related]
11. Inetetamab in combination with rapamycin and chemotherapy for trastuzumab-treated metastatic human epidermal growth factor receptor 2-positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway.
Wang A; Li C; Jiang Q; Jiang S
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1864. PubMed ID: 37501598
[TBL] [Abstract][Full Text] [Related]
12. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
13. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
Gordon MA; D'Amato NC; Gu H; Babbs B; Wulfkuhle J; Petricoin EF; Gallagher I; Dong T; Torkko K; Liu B; Elias A; Richer JK
Mol Cancer Ther; 2017 Jul; 16(7):1389-1400. PubMed ID: 28468774
[TBL] [Abstract][Full Text] [Related]
14. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.
Eroglu Z; Tagawa T; Somlo G
Oncologist; 2014 Feb; 19(2):135-50. PubMed ID: 24436312
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
Ding X; Sharko AC; McDermott MSJ; Schools GP; Chumanevich A; Ji H; Li J; Zhang L; Mack ZT; Sikirzhytski V; Shtutman M; Ivers L; O'Donovan N; Crown J; Győrffy B; Chen M; Roninson IB; Broude EV
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2201073119. PubMed ID: 35914167
[TBL] [Abstract][Full Text] [Related]
17. Treatment of HER2-positive metastatic breast cancer following initial progression.
Mayer IA
Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S50-7. PubMed ID: 19596643
[TBL] [Abstract][Full Text] [Related]
18. Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.
Sonnenblick A; Brohée S; Fumagalli D; Vincent D; Venet D; Ignatiadis M; Salgado R; Van den Eynden G; Rothé F; Desmedt C; Neven P; Loibl S; Denkert C; Joensuu H; Loi S; Sirtaine N; Kellokumpu-Lehtinen PL; Piccart M; Sotiriou C
BMC Med; 2015 Aug; 13():177. PubMed ID: 26234940
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
Wong H; Yau T
Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways.
Brouxhon SM; Kyrkanides S; Teng X; Raja V; O'Banion MK; Clarke R; Byers S; Silberfeld A; Tornos C; Ma L
Clin Cancer Res; 2013 Jun; 19(12):3234-46. PubMed ID: 23620408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
